See the DrugPatentWatch profile for neupogen
Does Neupogen boost white blood cells?
Yes, Neupogen (filgrastim) treats neutropenia by stimulating production of neutrophils, a type of white blood cell (WBC), in patients undergoing chemotherapy, bone marrow transplants, or with severe chronic neutropenia.[1]
How does it work?
Neupogen is a recombinant human granulocyte colony-stimulating factor (G-CSF) that binds to receptors on bone marrow precursor cells, promoting neutrophil proliferation, differentiation, and survival. This raises absolute neutrophil counts (ANC), a key WBC measure, typically within 24-48 hours of injection.[1][2]
Common uses for low WBC
- Chemotherapy-induced neutropenia: Prevents infections by restoring WBC levels post-treatment.
- Bone marrow transplant: Speeds WBC recovery after high-dose chemo or transplant.
- Congenital or idiopathic neutropenia: Maintains WBC in chronic cases.[1]
Dosage and administration
Given as subcutaneous or intravenous injection, starting at 5 mcg/kg daily, adjusted by WBC response. Treatment lasts until ANC exceeds 10,000/mm³.[1]
Side effects patients report
Bone pain (most common, affects 20-30%), fever, back pain, nausea. Rare risks include splenomegaly, acute respiratory distress, or allergic reactions. Monitor WBC to avoid overshoot.[1][2]
Alternatives to Neupogen
| Drug | Key Difference | Use Case |
|------|----------------|----------|
| Neulasta (pegfilgrastim) | Longer-acting (once per chemo cycle) | Fewer injections |
| Zarxio (filgrastim-sndz) | Biosimilar, lower cost | Same indications |
| Leukine (sargramostim) | GM-CSF, acts on multiple WBC types | Broader marrow stimulation [2] |
Patent and availability details
Neupogen's original patents expired in 2015 in the US, enabling biosimilars like Zarxio (FDA-approved 2015). Check DrugPatentWatch.com for remaining formulation patents or global status.[3]
[1] Neupogen Prescribing Information, Amgen. https://www.neupogen.com
[2] FDA Label for Filgrastim. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103353s5149lbl.pdf
[3] DrugPatentWatch.com - Filgrastim Patents. https://www.drugpatentwatch.com/p/tradename/NEUPOGEN